Partial
Mostly Aligned
Patient Risk:
High
Summary
Several key claims (indications, general single-dose use, and listed common adverse events) align with the supplied label excerpts, but multiple important mismatches/unsupported statements exist—most notably age indications (12+ vs 5+), omission of weight-based dosing tables for the 80 mg claim, and unsupported/overreaching assertions regarding generic availability and viral replication mechanism details.
Category Scores
Accurate Statements
Baloxavir marboxil is an antiviral medication used to treat acute uncomplicated influenza.
Supported by label excerpt 1.1 Treatment of Influenza indicating XOFLUZA (baloxavir marboxil) is indicated for treatment of acute uncomplicated influenza (age criterion differs; see contradictions/omissions).
Baloxavir marboxil functions by inhibiting the cap-dependent endonuclease activity of the influenza virus.
Supported by label mechanism excerpt: Baloxavir inhibits the endonuclease activity of the PA protein required for viral gene transcription (12 Clinical Pharmacology excerpts).
By blocking cap-dependent endonuclease activity, baloxavir marboxil prevents the virus from making copies of itself.
Partially supported as a consequence of the labeled mechanism (inhibits endonuclease required for viral gene transcription); however specific wording is broader than the excerpt.
Xofluza is manufactured and marketed by Shionogi Inc.
Not supported/contradicted by the provided label excerpts.
Baloxavir marboxil offers a different mechanism of action compared to neuraminidase inhibitors.
Not explicitly stated in provided excerpts; but may be consistent with the provided mechanism vs neuraminidase inhibitors. No direct label wording provided.
Baloxavir marboxil is a single-dose oral medication.
Supported by label excerpt 2.2: 'Take XOFLUZA as a single dose.'
The most common adverse events include diarrhea, bronchitis, nausea, sinusitis, and headache.
Supported by label excerpt 6.1: 'most common adverse events... includes diarrhea, bronchitis, nausea, sinusitis, headache...'
Vomiting is reported in pediatric subjects 5 to <12 years as an AE (≥5%).
Supported by label excerpt 6.1: pediatric subjects most frequently reported AEs (≥5%) include vomiting (5%) and diarrhea (5%).
Untreated influenza can lead to serious complications including pneumonia.
Not supported by provided label excerpts.
Unsupported Statements
Xofluza is manufactured and marketed by Shionogi Inc.
No manufacturing/marketing company information is present in the provided label excerpts.
Common side effects associated with baloxavir marboxil include nasopharyngitis.
Provided label excerpt lists common adverse events including diarrhea, bronchitis, nausea, sinusitis, headache; nasopharyngitis is not included in the supplied excerpt.
Common side effects associated with baloxavir marboxil include nasopharyngitis (common cold symptoms).
Nasopharyngitis and its mapping to common cold symptoms are not supported by the supplied label excerpts.
For treatment of influenza, the typical dosage for patients 12 years and older is 80 mg administered as a single oral dose.
Label excerpt 2.2 specifies weight-based dosing with Table dosing summaries (40 mg or 80 mg depending on weight), and indication age is 5+ not 12+; 'typical dosage' of 80 mg for all ≥12 is not supported.
For post-exposure prophylaxis, the dosage of baloxavir marboxil is 80 mg administered as a single oral dose.
Label excerpt 2.2 states a single weight-based dose displayed in Tables; it does not support a single fixed 80 mg for all eligible patients.
The availability of generic versions of baloxavir marboxil depends on the expiry of its associated patents and any potential legal challenges to those patents.
No patent/generic availability discussion appears in the provided label excerpts.
Once patents expire and regulatory hurdles are cleared, generic manufacturers can produce and market their versions of baloxavir marboxil.
No such generics/patent/legal timeline content appears in the provided label excerpts.
The cap-dependent endonuclease activity is crucial for viral replication because it cleaves host cell mRNA to generate primers for viral RNA synthesis.
The provided mechanism excerpt only states inhibition of endonuclease activity required for viral gene transcription; the detailed claim about cleaving host cell mRNA and generating primers is not supported by the supplied excerpts.
Untreated influenza can lead to serious complications including bronchitis.
No label excerpt provided supports complications list statements for 'untreated influenza' (other than general warning that serious bacterial infections may begin with influenza-like symptoms).
Untreated influenza can lead to serious complications including sinus infections.
Not supported by the provided label excerpts.
Untreated influenza can lead to serious complications including ear infections.
Not supported by the provided label excerpts.
In some cases, influenza can worsen chronic health problems such as asthma, diabetes, or heart disease.
No such statement appears in the provided label excerpts.
Baloxavir marboxil is used for post-exposure prophylaxis to prevent influenza in individuals aged 12 years and older after close contact with an infected person.
The label excerpt supports post-exposure prophylaxis in persons 5 years and older, but not the '12 years and older' age threshold in the provided excerpt.
Baloxavir marboxil is an antiviral medication used to treat acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours.
The label excerpt supports treatment in patients 5 years and older; '12 years and older' is not supported by provided excerpt.
Baloxavir marboxil offers a different mechanism of action compared to neuraminidase inhibitors.
While the label excerpt provides its MOA, it does not explicitly compare to neuraminidase inhibitors in the supplied text.
Contradictions
High
AI Statement
Baloxavir marboxil is an antiviral medication used to treat acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours.
Label Reference
1.1 Treatment of Influenza: indicated for patients 5 years of age and older (not 12+).
High
AI Statement
Baloxavir marboxil is used for post-exposure prophylaxis to prevent influenza in individuals aged 12 years and older after close contact with an infected person.
Label Reference
1.2 Post-Exposure Prophylaxis of Influenza: indicated for persons 5 years of age and older (not 12+).
High
AI Statement
For treatment of influenza, the typical dosage for patients 12 years and older is 80 mg administered as a single oral dose.
Label Reference
2.2 Recommended Dosage: dosage is weight-based (Tables) and indication age is 5+; fixed 80 mg for all ≥12 is inconsistent with provided table summaries.
High
AI Statement
For post-exposure prophylaxis, the dosage of baloxavir marboxil is 80 mg administered as a single oral dose.
Label Reference
2.2 Recommended Dosage: single weight-based dose displayed in Tables (not fixed 80 mg for all).
Low
AI Statement
Common side effects associated with baloxavir marboxil include nasopharyngitis.
Label Reference
6.1 Clinical Trials Experience excerpt provided does not list nasopharyngitis among the most common adverse events in the supplied excerpt.
Important Omissions
Weight-based dosing details (Tables for tablets/suspension, including 40 mg vs 80 mg depending on weight) were not included despite the AI providing a fixed 80 mg dosage claim.
Importance:
High
Key administration timing/handling instructions for oral suspension (e.g., for bottle reconstitution, administration within 10 hours) were not mentioned.
Importance:
Moderate
Drug interaction avoidance with dairy/calcium-fortified beverages, antacids, polyvalent cation-containing laxatives, and oral supplements (calcium/iron/magnesium/selenium/zinc) was omitted.
Importance:
Moderate
Contraindication information regarding hypersensitivity to baloxavir marboxil/ingredients was not addressed.
Importance:
Moderate
Label warning that XOFLUZA is not indicated in patients <5 years due to increased incidence of treatment-emergent resistance was omitted.
Importance:
Moderate
Warning that XOFLUZA has not been shown to prevent complications from illnesses caused by pathogens other than influenza viruses (including bacterial infections beginning with influenza-like symptoms) was not included.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple high-severity mismatches: incorrect age thresholds (label indicates 5+), incorrect fixed 80 mg dosing instead of weight-based dosing, and missing key interaction/handling contraindication-related content. These could lead to improper patient selection or dosing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Incorrect age inclusion criteria (12+ stated vs 5+ in label) and incorrect dosing statements (fixed 80 mg vs weight-based dosing tables).
Suggested Improvement
Replace '12 years and older' with '5 years of age and older' for both treatment and post-exposure prophylaxis, and state the label-recommended weight-based single dose (40 mg vs 80 mg; suspension packet/bottle equivalents) instead of a fixed 80 mg dose. Add the label’s key interaction avoidance (dairy/calcium and polyvalent cations) and relevant administration/handling timing for reconstituted oral suspension if discussing practical use.